Abstract Purpose : Amniograft is a new generation of therapies designed to accelerate the regeneration of damaged ocular surface tissue from chronic ulcers, wounds, keratopathy, pterygium, chemical burns, corneal scars, conjunctivochalasis and a wide array of ocular surface diseases. Amniograft will be used after failure of all other medications and autografts

Materials : Cryopreserved (-80 C) of the innermost layer of the human amniotic membrane of the placenta stored after cesarean section, which retains natural growth factors, cytokines and no growth of microorganisms. Mothers are screened for HIV, Hepatitis (B,C), syphilis and other necessary tests with consent. Methods : Amniograft (allograft) is used in surgical settings and is attached to the ocular surface with sutures or fibrin glue and prokera (sutureless: polycarbonate ring as a biologic bandage).

Results: Amniotic membrane (allograft) facilitates the short term success of epithelial damaged repair and promotes healing via natural healing to restore ocular surface function.

Conclusion: Amniograft has long term stability with minimal inflammation, pain, discomfort, scarring and antiangiogenic when used as indicated. In addition, for optimal surgical results, use necessary antibiotic(s) in a few cases of Amniograft infection after smears and cultures.